🔗 Share this article

While America undertakes sweeping adjustments to its vaccination schedules, an unexpected name has surfaced in a surprising turn: Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccinations during the pandemic and has concentrated on potential fatalities following COVID-19 vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Immunization Schedule

Public health authorities planned to reveal sweeping revisions to the pediatric immunization program in December, aligning the US with Denmark’s immunization schedule, sources say – a major change that would put the US out of alignment with many the world with insufficient data for public health gain. The announcement has been delayed until the coming year.

In place of the top vaccines chief, Dr. Høeg is scheduled to address the audience at the meeting. She was recently named acting director of the FDA’s CDER, the fifth appointee to lead the office this calendar year.

A New Direction at the Agency

The acting appointment might represent a tighter collaboration between the drug and biologics centers as Høeg and Dr. Prasad solidify control at the agency – and it points to a greater focus upon dismantling already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric vaccine recommendations in the US in order to be more similar to the Danish model, a nation with comprehensive healthcare and a population roughly the size of Wisconsin’s.

To date statements, she has continued to focus on vaccination policy – usually the purview of Dr. Prasad, chief of the FDA’s vaccine center – rather than medication approval.

Doubts Over Qualifications

Dr. Høeg has no apparent background in pharmaceutical research, regulation or management, which has been typical for past directors of the CBER. She has worked at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She has not conducted a scientific study. She is not versed in managing a large organization. She lacks background in drug approvals.”

Former commissioners of CBER would “understand legal statutes and the underlying principles of drug development”, noted Janet Woodcock. “Clearly, she doesn’t have the kind of background that previous people who headed the center have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock stated.

“Everybody just focuses on the new drug program, but the generic program clears numerous generic medications. There is also a biosimilars division, OTC medication office and so forth, and all of those need to be supervised,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a significant leadership aspect to the position, which manages over 5,000 staff members. “It’s a massive administrative position, if you perform it correctly,” Woodcock concluded.

Response and Contentious Policies

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment indicates greater collaboration among agency officials on vaccines, a representative responded that the “concerns stem from inaccurate presumptions”.

“Her resume is consistent with the duties of her role,” the spokesperson explained, noting the months Høeg spent advising the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's controversial priority voucher program, a contentious expedited therapy clearance system that allegedly concerned her predecessors. “By what process are these therapies being picked for this fast-track system? Who is making the choices?” Dr. Howard said. “There is a lot of secrecy going on at the agency right now.”

In general, he stated, “the Food and Drug Administration seems to be moving towards more relaxed regulations of pharmaceuticals, except for shots.”

Documented Past Work on Immunizations

Regarding vaccines, Høeg has a more established, if concerning, track record, critics said. She authored a study using unconfirmed crowd-sourced reports to assess the rate of myocarditis after COVID-19 immunization. She advised the Florida top health official Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are pose a greater threat than they are.

Part of her “wish list” for the current government encompassed changing guidelines for novel immunizations and discontinuing “optional” vaccines, she remarked following the vote on a audio program. At the FDA, Høeg has according to sources suggested barring teenage boys from getting COVID-19 vaccines.

“She’s an complete true believer who commences with her beliefs and tailors the evidence to fit the data in a highly misleading, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|